Beth M Piraino

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/29269/publications.pdf

Version: 2024-02-01

165 papers 8,495 citations

57758 44 h-index 89 g-index

170 all docs

170 docs citations

170 times ranked

4058 citing authors

#	Article	IF	Citations
1	Intraperitoneal pharmacokinetics of vancomycin in patients on automated peritoneal dialysis. Clinical and Translational Science, 2022, 15, 649-657.	3.1	3
2	ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Peritoneal Dialysis International, 2022, 42, 110-153.	2.3	209
3	Transferring From Peritoneal Dialysis to Hemodialysis: Proceed With Caution. Kidney International Reports, 2022, 7, 942-944.	0.8	1
4	Optimizing Peritoneal Dialysis–Associated Peritonitis Prevention in the United States. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 154-161.	4.5	5
5	Preparing for Peritoneal Dialysis. , 2020, , 1175-1185.		0
6	Peritoneal Dialysis–Related Infection Rates and Outcomes: Results From the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS). American Journal of Kidney Diseases, 2020, 76, 42-53.	1.9	120
7	Vancomycin in peritoneal dialysis: Clinical pharmacology considerations in therapy. Peritoneal Dialysis International, 2020, 40, 384-393.	2.3	15
8	Peritoneal dialysis-associated peritonitis outcomes reported in trials and observational studies: A systematic review. Peritoneal Dialysis International, 2020, 40, 132-140.	2.3	26
9	Regional variation in the treatment and prevention of peritoneal dialysis-related infections in the Peritoneal Dialysis Outcomes and Practice Patterns Study. Nephrology Dialysis Transplantation, 2019, 34, 2118-2126.	0.7	56
10	Review of Antibiotic Dosing with Peritonitis in APD. Peritoneal Dialysis International, 2019, 39, 299-305.	2.3	9
11	Putting Peritoneal Dialysis Catheter Infections Into Perspective. American Journal of Kidney Diseases, 2019, 74, 705-707.	1.9	1
12	Innovations in Treatment Delivery, Risk of Peritonitis, and Patient Retention on Peritoneal Dialysis. Seminars in Dialysis, 2017, 30, 158-163.	1.3	8
13	Outcomes of PD Patients at 6 Months. Peritoneal Dialysis International, 2017, 37, 116-118.	2.3	4
14	Effective Treatment of PD Peritonitis. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1919-1921.	4.5	2
15	The mystery of the nonfunctioning catheter: An unusual complication of peritoneal dialysis outflow failure. Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2017, 28, 405.	0.3	0
16	Long-Term Exit-Site Gentamicin Prophylaxis and Gentamicin Resistance in a Peritoneal Dialysis Program. Peritoneal Dialysis International, 2016, 36, 387-389.	2.3	14
17	ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment. Peritoneal Dialysis International, 2016, 36, 481-508.	2.3	745
18	No Difference in Average Interdialytic Weight Gain Observed in a Randomized Trial With a Technology-Supported Behavioral Intervention to Reduce Dietary Sodium Intake in Adults Undergoing Maintenance Hemodialysis in the United States: Primary Outcomes of the BalanceWise Study. , 2016, 26, 149-158.		38

#	Article	IF	CITATIONS
19	Organism-specific bacteremia by hemodialysis access. Clinical Nephrology, 2016, 86, 141-146.	0.7	17
20	Comparison of Survival of Patients with Heart and Lung Transplants on Peritoneal Dialysis and Hemodialysis. Peritoneal Dialysis International, 2015, 35, 98-101.	2.3	7
21	Dietary Sodium Intake in Type 2 Diabetes. Clinical Diabetes, 2014, 32, 106-112.	2.2	18
22	Loss of Kidney Function With Aging Is a Patient Safety Hazard. American Journal of Kidney Diseases, 2013, 62, 217-219.	1.9	2
23	Catheter-Related Peritonitis. Peritoneal Dialysis International, 2013, 33, 592-595.	2.3	3
24	Learning from the Children. Peritoneal Dialysis International, 2012, 32, 395-398.	2.3	0
25	A Decade After the KDOQI CKD Guidelines: Impact on the National Kidney Foundation. American Journal of Kidney Diseases, 2012, 60, 689-691.	1.9	5
26	Biophysiologic Outcomes of the Enhancing Adherence in Type 2 Diabetes (ENHANCE) Trial. Journal of the Academy of Nutrition and Dietetics, 2012, 112, 1147-1157.	0.8	35
27	TodayÂ's Approaches to Prevent Peritonitis. Contributions To Nephrology, 2012, 178, 246-250.	1.1	7
28	In Reply to â€~A Large Dialysis Provider Committed to Home Modalities'. American Journal of Kidney Diseases, 2012, 59, 739-740.	1.9	2
29	Examination of survival after transfer from peritoneal dialysis to hemodialysis. Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis, 2012, 28, 64-7.	0.1	4
30	Personal Digital Assistant-Based Self-Monitoring Adherence Rates in 2 Dialysis Dietary Intervention Pilot Studies: BalanceWise-HD and BalanceWise-PD., 2011, 21, 492-498.		21
31	When should the peritoneal dialysis catheter be removed for dialysisâ€related infections?. Seminars in Dialysis, 2011, 24, 443-444.	1.3	0
32	The economic value of screening haemodialysis patients for methicillin-resistant Staphylococcus aureus in the USA. Clinical Microbiology and Infection, 2011, 17, 1717-1726.	6.0	21
33	Systematic Barriers to the Effective Delivery of Home Dialysis in the United States: A Report From the Public Policy/Advocacy Committee of the North American Chapter of the International Society for Peritoneal Dialysis. American Journal of Kidney Diseases, 2011, 58, 879-885.	1.9	68
34	Preventing peritonitis in PD patients. Dialysis and Transplantation, 2011, 40, 367-371.	0.2	3
35	ISPD Position Statement on Reducing the Risks of Peritoneal Dialysis–Related Infections. Peritoneal Dialysis International, 2011, 31, 614-630.	2.3	273
36	Approaches to Preventing Peritonitis Based on Organism-Specific Rates. Peritoneal Dialysis International, 2011, 31, 636-638.	2.3	6

#	Article	IF	Citations
37	Nutritional Intake in Adult Hemodialysis Patients. Topics in Clinical Nutrition, 2011, 26, 45-56.	0.4	22
38	Criminal Background Checks Upon Acceptance to Medical School: The Right Policy at the Right Time. Academic Medicine, 2011, 86, 807.	1.6	1
39	Can We Reduce Rates of Staphylococcus Aureus and Other Peritonitis in Peritoneal Dialysis Patients?. Peritoneal Dialysis International, 2010, 30, 277-279.	2.3	3
40	Peritoneal Dialysis-Related Infections Recommendations: 2010 Update. Peritoneal Dialysis International, 2010, 30, 393-423.	2.3	770
41	The importance of peritoneal catheter exit-site care. Nature Reviews Nephrology, 2010, 6, 259-260.	9.6	9
42	Mupirocin for preventing exit-site infection and peritonitis in patients undergoing peritoneal dialysis. Was it effective?. Nephrology Dialysis Transplantation, 2010, 25, 349-352.	0.7	14
43	Peritonitis – Does Peritoneal Dialysis Modality Make a Difference?. Blood Purification, 2010, 29, 145-149.	1.8	22
44	<i>Clostridium difficile</i> Infections in Outpatient Dialysis Cohort. Infection Control and Hospital Epidemiology, 2010, 31, 89-91.	1.8	20
45	Sources of Variation in Estimates of Lean Body Mass by Creatinine Kinetics and by Methods Based on Body Water or Body Mass Index in Patients on Continuous Peritoneal Dialysis., 2010, 20, 91-100.		5
46	Effects of an intervention to improve communication about end-of-life care among African Americans with chronic kidney disease. Applied Nursing Research, 2010, 23, 65-72.	2.2	67
47	Does Experience with Pd Matter?. Peritoneal Dialysis International, 2009, 29, 256-261.	2.3	6
48	Cardiovascular Complications in Peritoneal Dialysis Patients. Contributions To Nephrology, 2009, 163, 102-109.	1.1	5
49	Insights on Peritoneal Dialysis-Related Infections. Contributions To Nephrology, 2009, 163, 161-168.	1.1	15
50	On Being a Nephrologist. Dialysis and Transplantation, 2009, 38, 112-112.	0.2	0
51	Randomized controlled trial of SPIRIT: An effective approach to preparing Africanâ€American dialysis patients and families for end of life. Research in Nursing and Health, 2009, 32, 260-273.	1.6	88
52	The United States' Perspectives on Home Dialysis. Advances in Chronic Kidney Disease, 2009, 16, 189-197.	1.4	18
53	Does experience with PD matter?. Peritoneal Dialysis International, 2009, 29, 256-61.	2.3	1
54	Clinical outcomes in peritoneal dialysis: impact of continuous quality provement initiatives. Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis, 2009, 25, 76-9.	0.1	21

#	Article	IF	CITATIONS
55	Why is Peritoneal Dialysis Underutilized in the United States?. Dialysis and Transplantation, 2008, 37, 90-90.	0.2	2
56	PSYCHOSOCIAL FACTORS IN PATIENTS WITH CHRONIC KIDNEY DISEASE: Quality of Life and Psychological Issues in Peritoneal Dialysis Patients. Seminars in Dialysis, 2008, 18, 119-123.	1.3	64
57	Subjective and Objective Sleep Quality in Patients on Conventional Thrice-Weekly Hemodialysis: Comparison With Matched Controls From the Sleep Heart Health Study. American Journal of Kidney Diseases, 2008, 52, 305-313.	1.9	76
58	Association of Kt/V and Creatinine Clearance With Outcomes in Anuric Peritoneal Dialysis Patients. American Journal of Kidney Diseases, 2008, 52, 1122-1130.	1.9	16
59	Design, feasibility, and acceptability of an intervention using personal digital assistant-based self-monitoring in managing type 2 diabetes. Contemporary Clinical Trials, 2008, 29, 396-409.	1.8	42
60	How should peritoneal-dialysis-associated peritonitis be treated?. Nature Clinical Practice Nephrology, 2008, 4, 356-357.	2.0	3
61	An Analysis of Methods to Prevent Peritoneal Dialysis Catheter Infections. Peritoneal Dialysis International, 2008, 28, 437-443.	2.3	22
62	A PDA-based dietary self-monitoring intervention to reduce sodium intake in an in-center hemodialysis patient. Patient Preference and Adherence, 2008, 2, 177-84.	1.8	12
63	An analysis of methods to prevent peritoneal dialysis catheter infections. Peritoneal Dialysis International, 2008, 28, 437-43.	2.3	10
64	Improvement in Pittsburgh Symptom Score index after initiation of peritoneal dialysis. Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis, 2008, 24, 46-50.	0.1	12
65	Opinion: Which of the K/DOQI Guidelines for Bone Disease in Dialysis Patients Should be Changed?. Seminars in Dialysis, 2007, 20, 24-26.	1.3	3
66	Opinion: Which of the K/DOQI Guidelines for Bone Disease in Dialysis Patients Should be Changed?. Seminars in Dialysis, 2007, 20, 28-30.	1.3	0
67	Guest Editor: Beth Piraino: Why Is the Evidence Favoring Hemodialysis over Peritoneal Dialysis Misleading?. Seminars in Dialysis, 2007, 20, 200-202.	1.3	9
68	Why Is the Evidence Favoring Hemodialysis over Peritoneal Dialysis Misleading?. Seminars in Dialysis, 2007, 20, 202-205.	1.3	0
69	Nurses and Physicians Working Together. Peritoneal Dialysis International, 2006, 26, 641-642.	2.3	4
70	The effect of coronary angiography on residual renal function in patients on peritoneal dialysis. Clinical Cardiology, 2006, 29, 494-497.	1.8	26
71	Characteristics of depression in hemodialysis patients: symptoms, quality of life and mortality risk. General Hospital Psychiatry, 2006, 28, 306-312.	2.4	180
72	Peritoneal Dialysis Infections Recommendations. , 2006, 150, 181-186.		12

#	Article	IF	CITATIONS
73	Does the risk of death differ between peritoneal dialysis and hemodialysis patients?. Nature Clinical Practice Nephrology, 2006, 2, 128-129.	2.0	4
74	Comparison of Infectious Complications between Incident Hemodialysis and Peritoneal Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 1226-1233.	4.5	113
75	Sleep Apnea in Patients on Conventional Thrice-Weekly Hemodialysis. Journal of the American Society of Nephrology: JASN, 2006, 17, 3503-3509.	6.1	156
76	The choice study. Peritoneal Dialysis International, 2006, 26, 423-5.	2.3	2
77	Nurses and physicians working together. Peritoneal Dialysis International, 2006, 26, 641-2.	2.3	2
78	An Introduction to the 2005 Peritoneal Dialysis-Related Infections Recommendations. Peritoneal Dialysis International, 2005, 25, 105-106.	2.3	1
79	Prevalence and Correction of 25(OH) Vitamin D Deficiency in Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2005, 25, 362-366.	2.3	84
80	Randomized, Double-Blind Trial of Antibiotic Exit Site Cream for Prevention of Exit Site Infection in Peritoneal Dialysis Patients. Journal of the American Society of Nephrology: JASN, 2005, 16, 539-545.	6.1	223
81	A Preliminary Study of PDA-Based Dietary Self-Monitoring in Hemodialysis Patients. , 2005, 15, 304-311.		30
82	Peritoneal dialysis-related infections recommendations: 2005 update. Peritoneal Dialysis International, 2005, 25, 107-31.	2.3	304
83	Prevalence and correction of 25(OH) vitamin D deficiency in peritoneal dialysis patients. Peritoneal Dialysis International, 2005, 25, 362-6.	2.3	42
84	The Effect of Depressive Symptoms on Survival in Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2004, 24, 256-263.	2.3	57
85	Bleeding Complications Associated with Peritoneal Dialysis Catheter Insertion. Peritoneal Dialysis International, 2004, 24, 478-480.	2.3	42
86	New insights on preventing and managing peritonitis. Pediatric Nephrology, 2004, 19, 125-127.	1.7	10
87	Methods to determine drain volume for peritoneal dialysis clearances. Peritoneal Dialysis International, 2004, 24, 182-5.	2.3	4
88	The effect of depressive symptoms on survival in peritoneal dialysis patients. Peritoneal Dialysis International, 2004, 24, 256-63.	2.3	22
89	Inter-rater reliability and annual rescoring of the Charlson comorbidity index. Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis, 2004, 20, 125-7.	0.1	26
90	Bleeding complications associated with peritoneal dialysis catheter insertion. Peritoneal Dialysis International, 2004, 24, 478-80.	2.3	10

#	Article	IF	Citations
91	Albumin at the start of peritoneal dialysis predicts the development of peritonitis. American Journal of Kidney Diseases, 2003, 41, 664-669.	1.9	88
92	A Dialysis Case Presentation and Discussion†Edited by Roger A. Rodby: Peritoneal Dialysis Catheter Replacement: "Save the Patient and Not the Catheter†Seminars in Dialysis, 2003, 16, 72-75.	1.3	11
93	Opinion: How Much Peritoneal Dialysis is Needed for Optimal Outcomes?. Seminars in Dialysis, 2003, 16, 367-369.	1.3	3
94	Dialysis Clinic: Cefazolin Use in Methicillin-Resistant Staphylococcal Peritonitis. Seminars in Dialysis, 2003, 16, 411-412.	1.3	0
95	Staphylococcus Aureus Prophylaxis and Trends in Gram-Negative Infections in Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2003, 23, 456-459.	2.3	74
96	Comparison of the Charlson Comorbidity Index and the Davies Score as a Predictor of Outcomes in PD Patients. Peritoneal Dialysis International, 2003, 23, 568-573.	2.3	55
97	Staphylococcus aureus prophylaxis and trends in gram-negative infections in peritoneal dialysis patients. Peritoneal Dialysis International, 2003, 23, 456-9.	2.3	35
98	Comparison of the Charlson Comorbidity Index and the Davies score as a predictor of outcomes in PD patients. Peritoneal Dialysis International, 2003, 23, 568-73.	2.3	28
99	Nightly intermittent peritoneal dialysis to initiate peritoneal dialysis. Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis, 2003, 19, 111-4.	0.1	7
100	Large Body Mass Index does not Predict Short-Term Survival in Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2002, 22, 191-196.	2.3	84
101	Ademex: How Should it Change our Practice?. Peritoneal Dialysis International, 2002, 22, 552-554.	2.3	19
102	A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. American Journal of Kidney Diseases, 2002, 40, 1055-1065.	1.9	179
103	Automated Peritoneal Dialysis Symposium: Intraâ€abdominal Pressure, Peritoneal Dialysis Exchange Volume, and Tolerance in APD. Seminars in Dialysis, 2002, 15, 403-406.	1.3	10
104	Large body mass index does not predict short-term survival in peritoneal dialysis patients. Peritoneal Dialysis International, 2002, 22, 191-6.	2.3	34
105	ADEMEX: how should it change our practice? Adequacy of Peritoneal Dialysis in Mexico. Peritoneal Dialysis International, 2002, 22, 552-4.	2.3	6
106	Placement of peritoneal dialysis catheters on an outpatient basis. Peritoneal Dialysis International, 2002, 22, 616-8.	2.3	5
107	Charlson Comorbidity Index as a Predictor of Outcomes in Incident Peritoneal Dialysis Patients. American Journal of Kidney Diseases, 2001, 37, 337-342.	1.9	203
108	Peritoneal Dialysis Clearance can Replace Residual Renal Function. Peritoneal Dialysis International, 2001, 21, 263-268.	2.3	5

#	Article	IF	CITATIONS
109	The Problem of Compliance with PDâ€∫Exchanges. Seminars in Dialysis, 2001, 13, 160-162.	1.3	4
110	<i>Staphylococcus aureus</i> Prophylaxis in Dialysis Patients. Blood Purification, 2000, 18, 350-354.	1.8	3
111	Peritoneal Infections. Advances in Chronic Kidney Disease, 2000, 7, 280-288.	2.1	24
112	Staphylococcus Aureus Infections in Dialysis Patients: Focus on Prevention. ASAIO Journal, 2000, 46, S13-S17.	1.6	49
113	latrogenic Peritonitis: The Need for Prophylaxis. Peritoneal Dialysis International, 2000, 20, 343-345.	2.3	22
114	Pattern of noncompliance with dialysis exchanges in peritoneal dialysis patients. American Journal of Kidney Diseases, 2000, 35, 1104-1110.	1.9	79
115	Is Small Molecule Clearance Dependent on Timing of Serum Sample and Mixing of Effluent in Ccpd Patients?. Peritoneal Dialysis International, 1999, 19, 391-393.	2.3	2
116	Gender Differences in Normalized Clearances in Capd: Role of Body Size and Normalizing Parameters. Peritoneal Dialysis International, 1999, 19, 165-169.	2.3	5
117	Tolerance of large exchange volumes by peritoneal dialysis patients. American Journal of Kidney Diseases, 1999, 33, 1136-1141.	1.9	30
118	Hospitalization in peritoneal dialysis patients. American Journal of Kidney Diseases, 1999, 33, 927-933.	1.9	76
119	The Relation Between Body Size and Normalized Small Solute Clearances in Continuous Ambulatory Peritoneal Dialysis. Journal of the American Society of Nephrology: JASN, 1999, 10, 1575-1581.	6.1	21
120	Peritoneal urea and creatinine clearances in continuous peritoneal dialysis patients with different types of peritoneal solute transport. Kidney International, 1998, 53, 1405-1411.	5.2	33
121	Patient Survival With Renal Replacement Therapy in Heart Transplantation Patients. ASAIO Journal, 1998, 44, M546-M548.	1.6	12
122	Outcomes of renal replacement therapy in orthotopic heart transplant patients. Current Opinion in Critical Care, 1998, 4, 364-367.	3.2	0
123	Nasal Mupirocin: Its Role in Dialysis Patients. Seminars in Dialysis, 1997, 10, 145-147.	1.3	3
124	National kidney foundation position paper on proposed health care financing administration guidelines for reimbursement of enteral and parenteral nutrition., 1996, 6, 45-47.		9
125	A randomized trial of staphylococcus aureus prophylaxis in peritoneal dialysis patients: Mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin. American Journal of Kidney Diseases, 1996, 27, 695-700.	1.9	217
126	Management of catheter-related infections. American Journal of Kidney Diseases, 1996, 27, 754-758.	1.9	15

#	Article	IF	Citations
127	Peritonitis associated with exit site and tunnel infections. American Journal of Kidney Diseases, 1996, 28, 415-419.	1.9	103
128	Reviews and Original Articles. Peritoneal Dialysis International, 1996, 16, 557-573.	2.3	192
129	Peritoneal Catheter Exit-Site and Tunne Infections. Advances in Chronic Kidney Disease, 1996, 3, 222-227.	2.1	7
130	Research Directions in Peritoneal Dialysis Infections. Blood Purification, 1995, 13, 171-179.	1.8	0
131	Proposed health care financing administration guidelines for reimbursement of enteral and parenteral nutrition. American Journal of Kidney Diseases, 1995, 26, 995-997.	1.9	19
132	The Prevention of <i>Staphylococcus uureus</i> Peritoneal DialysisRelated Infections. Seminars in Dialysis, 1995, 8, 355-358.	1.3	0
133	The Risks of Laparoscopic Cholecystectomy in Capd Compared with Hemodialysis Patients: A Study of Ten Patients. Peritoneal Dialysis International, 1994, 14, 395-396.	2.3	17
134	Infecting Organisms in Continuous Ambulatory Peritoneal Dialysis Patients on the Y-set. American Journal of Kidney Diseases, 1994, 23, 569-573.	1.9	81
135	Managing Staphylococcus aureus Catheter Infection in Continuous Ambulatory Peritoneal Dialysis Patients. Advances in Chronic Kidney Disease, 1994, 1, 167-175.	2.1	О
136	Alprazolam in end-stage renal disease. II. Pharmacodynamics. Clinical Pharmacology and Therapeutics, 1992, 51, 533-540.	4.7	17
137	Polymicrobial Peritonitis in Patients on Continuous Peritoneal Dialysis. American Journal of Kidney Diseases, 1992, 19, 162-166.	1.9	72
138	Increased Risk of Staphylococcus epidermidis Peritonitis in Patients on Dialysate Containing 1.25 mmol/L Calcium. American Journal of Kidney Diseases, 1992, 19, 371-374.	1.9	14
139	Calcium Mass Transfer With Dialysate Containing 1.25 and 1.75 mmol/L Calcium in Peritoneal Dialysis Patients. American Journal of Kidney Diseases, 1992 , 20 , $367-371$.	1.9	28
140	Hemoperitoneum Complicating Chronic Peritoneal Dialysis: Single-Center Experience and Literature Review. American Journal of Kidney Diseases, 1992, 19, 252-256.	1.9	77
141	The Use of Dialysate Containing 2.5 Meq/L Calcium in Peritoneal Dialysis Patients. Peritoneal Dialysis International, 1992, 12, 75-77.	2.3	23
142	Risk Factors for Tunnel Infections in Continuous Peritoneal Dialysis. American Journal of Kidney Diseases, 1991, 18, 344-348.	1.9	35
143	The Effect of Body Weight on CAPD Related Infections and Catheter Loss. Peritoneal Dialysis International, 1991, 11, 64-68.	2.3	55
144	Vestibular Toxicity Due to Gentamicin in Peritoneal Dialysis Patients. Peritoneal Dialysis International, 1991, 11, 152-155.	2.3	29

#	Article	IF	Citations
145	Catheter Infections in Insulin-Dependent Diabetics on Continuous Ambulatory Peritoneal Dialysis. Peritoneal Dialysis International, 1991, 11, 347-350.	2.3	18
146	Alprazolam in Endâ€Stage Renal Disease: I. Pharmacokinetics. Journal of Clinical Pharmacology, 1991, 31, 571-579.	2.0	21
147	An Intraperitoneal Insulin Regimen for Diabetics on Continuous Cyclic Peritoneal Dialysis. ASAIO Transactions, 1990, 36, 119.	0.2	1
148	Methicillin-Resistant Staphylococcal Infections in an Outpatient Peritoneal Dialysis Program. American Journal of Kidney Diseases, 1990, 16, 142-146.	1.9	22
149	The Effect of the Y-Set on Catheter Infection Rates in Continuous Ambulatory Peritoneal Dialysis Patients. American Journal of Kidney Diseases, 1990, 16, 46-50.	1.9	28
150	A Review of Staphylococcu S aureus Exit-Site and Tunnel Infections in Peritoneal Dialysis Patients. American Journal of Kidney Diseases, 1990, 16, 89-95.	1.9	52
151	Continuous Cycling Peritoneal Dialysis Is Associated With Lower Rates of Catheter Infections Than Continuous Ambulatory Peritoneal Dialysis. American Journal of Kidney Diseases, 1990, 16, 133-136.	1.9	79
152	Initiating a Peritoneal Dialysis Program: Personnel, Administrative Requirements, Patient Recruitment and Training. Seminars in Dialysis, 1990, 3, 122-126.	1.3	7
153	Operating a Peritoneal Dialysis Program: Patient and Program Monitoring. Seminars in Dialysis, 1990, 3, 182-186.	1.3	6
154	Complications of Peritoneal Dialysis: Diagnosis and Management. Seminars in Dialysis, 1990, 3, 245-248.	1.3	15
155	Hypercalcemia in Patients with Advanced Chronic Renal Failure Not Yet Requiring Dialysis. American Journal of Nephrology, 1989, 9, 205-210.	3.1	8
156	Elevated Bone Aluminum and Suppressed Parathyroid Hormone Levels in Hypercalcemic Dialysis Patients. American Journal of Nephrology, 1989, 9, 190-197.	3.1	14
157	Catheter Infections as a Factor in the Transfer of Continuous Ambulatory Peritoneal Dialysis Patients to Hemodialysis. American Journal of Kidney Diseases, 1989, 13, 365-369.	1.9	81
158	Resolution of hypercalcemia and aluminum bone disease after renal transplantation. American Journal of Medicine, 1988, 85, 728-730.	1.5	10
159	Analysis of continuous ambulatory peritoneal dialysis-related pseudomonas aeruginosa infections. American Journal of Medicine, 1987, 83, 829-832.	1.5	66
160	A Five-Year Study of the Microbiologic Results of Exit Site Infections and Peritonitis in Continuous Ambulatory Peritoneal Dialysis. American Journal of Kidney Diseases, 1987, 10, 281-286.	1.9	105
161	Spontaneous hypercalcemia in patients undergoing dialysis. Etiologic and therapeutic considerations. American Journal of Medicine, 1986, 80, 607-615.	1.5	21
162	Serum Electrolyte Patterns in End-Stage Renal Disease. American Journal of Kidney Diseases, 1986, 8, 98-104.	1.9	78

BETH M PIRAINO

#	Article	IF	CITATIONS
163	The Influence of Peritoneal Catheter Exit-Site Infections on Peritonitis, Tunnel Infections, and Catheter Loss in Patients on Continuous Ambulatory Peritoneal Dialysis. American Journal of Kidney Diseases, 1986, 8, 436-440.	1.9	126
164	Hypercalcemia in a Dialysis Patient. American Journal of Nephrology, 1986, 6, 388-395.	3.1	2
165	Peritoneal Eosinophils during Intermittent Peritoneal Dialysis. American Journal of Nephrology, 1984, 4, 152-157.	3.1	37